46 results about "Haemoglobin A1c" patented technology

Provided is a device and a method, said device enabling the measurement of both of blood glucose level and hemoglobin A1c level, being small-sized and thus portable, allowing the measurement of a small amount of a specimen and, therefore, being usable in POC. The device for measuring the blood glucose level and hemoglobin A1c level of a blood specimen comprises: a test piece-mounting section (1) for detachably mounting test pieces (200) on which the blood specimen is to be spotted; a light-emitting section (2) for emitting light for irradiating the test pieces (200); a light-receiving section (3) for receiving reflected lights from the test pieces (200); and an operating section (4) for calculating the blood glucose level and hemoglobin A1c level of the blood specimen on the basis of photometric values obtained from the light-receiving section (3). As a test piece (200) for measuring the blood glucose level of the blood specimen, a test piece (A), which carries a composition (a) reacting with glucose and showing color development, is mounted. As a test piece (200) for measuring the hemoglobin A1c level of the blood specimen, a test piece (B), which carries a composition (b) reacting with glycated hemoglobin and showing color development, is mounted.

The purpose of the present invention is to provide: a method for measuring hemoglobins, which can measure hemoglobins within a short time and with high accuracy; and a method for measuring hemoglobin A1c, a method for measuring hemoglobin A1c and hemoglobin F simultaneously, a method for measuring hemoglobin A1c and hemoglobin A2 simultaneously and a method for measuring hemoglobin A1c and an abnormal hemoglobin simultaneously, each of which utilizes the above-mentioned method for measuring hemoglobins. The present invention is a method for measuring hemoglobins by liquid chromatography using a column which has cation-exchangeable particles filled therein as a column filler and has a pressure value of 9.8 plus103 to 29.4 plus105 Pa inclusive when an eluent to be used for the measurement is fed therethrough at a flow rate of 1.0 mL / minute, wherein the cation-exchangeable particles comprise crosslinked polymer particles and a polymer containing a cation-exchange group and provided on the surfaces of the crosslinked polymer particles.

Means that enables an immunoassay of hemoglobin A1c in a whole blood sample without pretreatment of the sample is disclosed. The immunoassay of hemoglobin A1c in a sample according to the present invention comprises bringing latex particles into contact with a non-pretreated whole blood sample in a hypotonic solution, and then bringing hemoglobin A1c adsorbed on the latex particles into contact with an anti-hemoglobin A1c antibody. The immunoassay is preferably carried out by an agglutination method. The hypotonic solution is, for example, a buffer containing a Good's buffer at a concentration of 0.02 to 0.2 mol / L, which Good's buffer has the maximum buffer capacity in the neutral to alkaline region.

Provided is an amadoriase characterized in acting on the beta-chains of hemoglobin A1c (HbA1c) to generate hydrogen peroxide. A HbA1c measurement method and measurement reagent kit using same are also provided. A HbA1c measurement method uses an amadoriase characterized in having a specific activity of 0.1 U / mg or more with respect to alphaF6P and in oxidizing the amino terminus of the beta-chains of HbA1c to generate hydrogen peroxide, and a measurement reagent kit comprises said amadoriase. The present invention provides a measurement method and measurement kit that are able to quantify HbA1c rapidly, easily and with good precision.

The invention provides biomarkers including β-2-microglobulin, Cystatin C, hsCRP and glucose as well as methods for using the biomarkers for diagnosing and / or assessing the risk of peripheral artery disease in a subject. In some embodiments, the subject being tested may be suffering from or at risk of other circulatory diseases, including coronary artery disease. Hemoglobin A1c or other proxies for measuring glucose levels may be substituted for or measured in addition to glucose in the context of the present invention.

Provided is a novel means for suitably maintaining the dispersion state of a latex reagent in an immunoassay kit and preventing the occurrence of coagulation and sedimentation due to changes in temperature so that a reagent is protected from deterioration in measurement performance, said means also being applicable to immunoagglutination measurement kits in which a small amount of a latex reagent is dispensed. An immunoassay reagent according to the present invention comprises unsensitized latex particles and trimethyl glycine in a solvent. The concentration of trimethyl glycine in the reagent is preferably 5-10 w / v%. The reagent can be suitably used as an immunoassay reagent for hemoglobin A1c, for example.

An object of the present invention is to provide a method for measuring hemoglobin that enables short-time, high-accuracy measurement of hemoglobin, in particular stable hemoglobin A1c, which is used as a diagnostic indicator of diabetes mellitus, and an electrophoresis apparatus that is suitably used in this measurement method. The present invention provides a method for measuring hemoglobins using electrophoresis, which includes: using a migration path having an inner surface coated with a cationic substance to be immobilized on the inner surface or a migration path having an inner surface made of a cationic material; and using a buffer solution containing a water-soluble polymer having an anionic group as an electrophoresis buffer solution.

Diabetes mellitus is characterized by either the inability to produce insulin (Type 1 diabetes) and or as insensitivity to insulin secreted by the body (Type 2 diabetes). In either case, the body is unable to efficiently move blood glucose across cell membranes to be utilized. This leads to a variety of local and systemic detrimental effects. Current treatments for diabetes focus on exogenous insulin administration and dietary control. Provided herein are treatments of diabetes using a cellular therapy to ameliorate symptoms associated with both reduced insulin secretion and insulin sensitivity. Using induced-pluripotent stem (iPS) cells, beta-like (ss-like) cells similar to the endogenous insulin secreting cells were derived.; These ss-like cells secreted insulin in response to glucose, and corrected a hyperglycemic phenotype in a mouse model of Type 2 diabetes via an iPS cell transplant. Within the Type 2 diabetes mouse model, a long term correction of hyperglycemia was achieved as measured by blood glucose and hemoglobin AIc measurements. Reduction of hyperglycemia was also seen in a chemically-induced mouse model for Type 1 diabetes.

The disclosure also relates to novel compositions and methods for the single, direct detection of Hemoglobin A1c percentage in a sample, using conversion of functional groups attached to a transitional metal complex, resulting in quantifiable electrochemical signal at two unique potentials, Eo1 and Eo2.